PolarityTE to Present at the H.C. Wainwright 24th Annual Global Investment Conference on September 14, 2022

Rhea-AI Summary

PolarityTE, Inc. (Nasdaq: PTE), a biotechnology firm based in Salt Lake City, announced its presentation at the H.C. Wainwright 24th Annual Global Investment Conference in New York City. The presentation is scheduled for September 14, 2022, at 11:00 am ET. PolarityTE specializes in developing regenerative tissue products and biomaterials, with its flagship product, SkinTE, currently under investigational use and pending pivotal studies for FDA approval. For more details, visit www.PolarityTE.com.

SALT LAKE CITY, Sept. 13, 2022 /PRNewswire/ -- PolarityTE, Inc. (Nasdaq: PTE), a biotechnology company developing regenerative tissue products and biomaterials, today announced it will present at the H.C. Wainwright 24^th Annual Global Investment Conference in New York City at 11:00 am, ET, on September 14, 2022. 

About PolarityTE®
PolarityTE, Inc., headquartered in Salt Lake City, Utah, is a biotechnology company developing regenerative tissue products.  PolarityTE's first regenerative tissue product is SkinTE®.  PolarityTE has an open investigational new drug application (IND) for SkinTE® with the U.S. Food and Drug Administration (FDA) and is now pursuing the first of two pivotal studies on SkinTE® needed to support a biologics license application (BLA).  SkinTE® is available for investigational use only. Learn more at www.PolarityTE.com.

Forward Looking Statements
Certain statements contained in this release are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. They are generally identified by words such as "believes," "may," "expects," "anticipates," "intend," "plan," "will," "would," "should" and similar expressions. Readers should not place undue reliance on such forward-looking statements, which are based upon the Company's beliefs and assumptions as of the date of this release. The Company's actual results could differ materially due to the impact of the COVID-19 pandemic, future clinical studies, and FDA regulatory matters, which cannot be predicted, and the risk factors and other items described in more detail in the "Risk Factors" section of the Company's Annual Reports and other filings with the SEC (copies of which may be obtained at www.sec.gov). Subsequent events and developments may cause these forward-looking statements to change. The Company specifically disclaims any obligation or intention to update or revise these forward-looking statements as a result of changed events or circumstances that occur after the date of this release, except as required by applicable law.

POLARITYTE, the POLARITYTE logo, SKINTE, WHERE SELF REGENERATES SELF and WELCOME TO THE SHIFT are registered trademarks of PolarityTE, Inc.

CONTACTS

Investors:
PolarityTE Investor Relations
ir@PolarityTE.com 
385-831-5284

Media:
David Schull or Ignacio Guerrero-Ros
David.schull@russopartnersllc.com 
Ignacio.guerrero-ros@russopartnersllc.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/polarityte-to-present-at-the-hc-wainwright-24th-annual-global-investment-conference-on-september-14-2022-301622551.html

SOURCE PolarityTE, Inc.

FAQ

When is PolarityTE presenting at the H.C. Wainwright conference?

PolarityTE will present on September 14, 2022, at 11:00 am ET.

Where is the H.C. Wainwright 24th Annual Global Investment Conference held?

The conference is held in New York City.

What is the focus of PolarityTE's presentation?

The presentation will likely focus on PolarityTE's regenerative tissue products and biomaterials.

What product is PolarityTE developing?

PolarityTE is developing a regenerative tissue product called SkinTE.

What is the status of SkinTE with the FDA?

SkinTE has an open investigational new drug application and is pursuing pivotal studies for FDA approval.